Authored By: Sarah
11 Jul 2024

 Anorexiants Market Size to grow by USD 1023.4 million between 2024-2028

According to a research report “ Anorexiants Market” by Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 1023.4 million, at a CAGR of  4.5% during the forecast period. Obesity poses a significant challenge to global public health, with its association to chronic conditions such as diabetes, hypertension, and cancer. The prevalence and incidence of obesity continue to rise due to sedentary lifestyles and limited effectiveness of existing obesity treatments. The US has seen the highest obesity prevalence in the past two decades. In response, consumers are increasingly prioritizing health consciousness as they grapple with the consequences of obesity, cardiovascular diseases, and diabetes. This market trend presents a substantial business opportunity for anorexiants, which are medications used to suppress appetite and promote weight loss. These drugs offer a potential solution for individuals seeking effective obesity management options.

Browse market data tables, figures, and in-depth TOC on “Anorexiants Market” by Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample


By Distribution Channel, the Hospital pharmacy segment is projected to dominate the market size in 2024


By Geography, North America  segment is expected to hold the largest market size for the year 2024

The anorexiants market refers to the pharmaceutical industry segment specializing in the production and distribution of medications used to suppress appetite and induce weight loss. These drugs, primarily prescribed for individuals diagnosed with eating disorders such as anorexia nervosa, are essential for managing symptoms and improving patient health. Market growth is driven by rising prevalence rates of eating disorders, increasing awareness, and advancements in drug development. Companies in this sector focus on innovation and regulatory compliance to meet evolving patient needs and market demands.

North America is forecasted to hold the largest market size by region in 2024

The anorexiants market refers to the pharmaceutical industry segment specializing in appetite suppressants. These medications are essential for managing weight loss treatments for individuals struggling with obesity and other related health conditions. Market growth is driven by increasing obesity rates worldwide, regulatory approvals for new anorectic drugs, and rising consumer awareness of weight management solutions. Companies are investing in research and development to produce safer and more effective anorexic agents, thereby expanding the market's potential.

The Anorexiants Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Bausch Health Companies Inc.
  • Currax Pharmaceuticals LLC
  • Elite Pharmaceuticals Inc.
  • Epic Pharma LLC
  • F. Hoffmann La Roche Ltd.
  • Hi Tech Pharmaceuticals
  • Intas Pharmaceuticals Ltd.
  • Johnson and Johnson Services Inc.
  • KVK Tech Inc.
  • Lannett Co. Inc.
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc.
  • Recordati S.p.A
  • Searchlight Pharma Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Virtus Nutrition LLC
  • Zydus Lifesciences Ltd.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Title: Anorexiants Market: Oral and Subcutaneous Formulations for Weight Loss and Other Indications The global anorexiants market encompasses a range of oral and subcutaneous formulations used for weight loss and the management of various medical conditions. These anorexiants can be broadly categorized into serotonin anorexiants and catecholamines anorexiants. Oral anorexiants include capsules and tablets of various pharmaceutical compounds, such as phentermine, diethylpropion, and phenylpropanolamine. CNS stimulants like amphetamines and methylphenidate are also used as anorexiants for weight loss and attention deficit hyperactivity disorder (ADHD). Subcutaneous anorexiants, such as leptin and metreleptin, are administered through injections for the treatment of conditions like Lennox Gastaut Syndrome and Dravet Syndrome. Anorexiants find applications in homecare settings, specialty clinics, and hospitals. They are used to address health issues like obesity, unhealthy dietary habits, physical inactivity, and sedentary lifestyles, which contribute to conditions like hypertension, diabetes, cardiovascular diseases, and more. The World Health Organization (WHO) recognizes the importance of anorexiants in managing weight loss and associated health issues. However, their use is subject to medical supervision due to potential side effects and risks.

Market Research Overview

The Appetite suppressants market encompasses a range of medications used to reduce feelings of hunger and aid in weight loss. According to the Epidemiology of obesity, over 1.9 billion adults were overweight or obese in 2016. Adherence rates to appetite suppressants are often low due to their Side effects, which include Vomiting, Nausea, Insomnia, Myalgia, Headache, Tachycardia, and Diarrhea. Mortality risks are increased in individuals using these medications, especially in those with a history of Cardiovascular disease, Endometrial cancer, Type 2 diabetes, Colon cancer, and Breast cancer. Drug development for appetite suppressants includes Branded drugs like Phentermine, Lorcaserin, Liraglutide, Orlistat, and Naltrexone. Serotonin Anorexiants and Catecholamines Anorexiants are two main classes, acting on the Limbic parts of the Brain, including the Hypothalamus, to suppress appetite. Side effects and safety concerns have led to ongoing research and development of new medications, such as LorcaserinER, which offers extended-release satiety effects. Appetite suppressing medications are available in various forms, including Capsules, Tablets, and subcutaneous or oral administration. The use of appetite suppressants is not limited to adults; they are also prescribed for Children and adolescents with Binge eating disorder and certain chronic diseases. Healthcare expenditure on these medications is substantial, with availability through Specialty Clinics, Hospitals, Homecare, Retail pharmacy, and Online pharmacy. It is essential to consider the underlying causes of obesity, such as Bad nutrition, Family lifestyle, Genetics, Inactivity, and Musculoskeletal issues, when considering the use of appetite suppressants. Regular exercise and a Low calorie diet are crucial components of weight loss and overall health. The World Health Organization recognizes obesity as a global health concern, with contributing factors including Hypertension, Diabetes, Cardiovascular diseases, and Unhealthy dietary habits. Pharmaceutical compounds and Drugs, like appetite suppressants, play a role in managing obesity, but they should be used in conjunction with lifestyle modifications for optimal health outcomes. CNS stimulants are another class of appetite suppressants used to treat conditions like ADHD, Lennox Gastaut Syndrome, and Dravet Syndrome. These medications work by increasing the levels of certain neurotransmitters in the brain, leading to increased focus and decreased appetite. In summary, the Appetite suppressants market offers various medications to help manage hunger and aid in weight loss. However, it is crucial to consider the potential side effects, safety concerns, and underlying causes of obesity when determining the appropriate use of these medications. Skilled professionals should be consulted for individualized treatment plans, which may include a combination of medications, lifestyle modifications, and regular monitoring.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Read News Read Less
Interested in this report?
Get your sample now!